Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

GSK3368715 (dihydrochloride)

GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8) ) . GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1].

Product Specifications

CAS Number

1628925-77-8

Product Name Alternative

EPZ019997 (dihydrochloride)

UNSPSC

12352005

Target

Histone Methyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gsk3368715-dihydrochloride.html

Purity

99.96

Solubility

DMSO : 200 mg/mL (ultrasonic) |H2O : 140 mg/mL (ultrasonic)

Smiles

CNCCN(CC1=CNN=C1C2CCC(COCC)(COCC)CC2)C.Cl.Cl

Molecular Formula

C20H40Cl2N4O2

Molecular Weight

439.46

References & Citations

[1]Fedoriw A, et al. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell. 2019 Jul 8;36 (1) :100-114.e25.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, stored under nitrogen, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 1

Isoform

PRMT1; PRMT3; PRMT4; PRMT6; PRMT8

Citation 01

Cell Death Dis. 2021 Nov 13;12 (11) :1080.|Cell Rep. 2023 Mar 29;42 (4) :112316.|Cell Rep. 2024 Aug 22;43 (9) :114662.|Front Pharmacol. 2020 Sep 8;11:569661.|Mol Carcinog. 2023 Aug;62 (8) :1119-1135.|Nat Chem Biol. 2024 Dec;20 (12) :1566-1576.|Nat Commun. 2023 Feb 23;14 (1) :1011.|Patent. US20240261260A1.|Research Square Preprint. 2022 Jul.|Sci Adv. 2023 Sep 8;9 (36) :eadi2232.|Transl Oncol. 2025 Jan 3:52:102264.|University of Washington. 2025.|Bone Rep. 2023 Jul 25:19:101704.|FASEB J. 2025 Jan 15;39 (1) :e70293.|Mol Carcinog. 2023 Aug;62 (8) :1119-1135.|Research Square Print. 26 Oct, 2022|Research Square Print. September 20th, 2022.|University of Munich. Fakultät für Medizin. 2022 Oct.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

MUC2 (CCP58), CF568 conjugate, 0.1mg/mL
BNC680032-500 1x 500 µL

MUC2 (CCP58), CF568 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD11a (Cris-3), CF740 conjugate, 0.1mg/mL
BNC740151-100 1x 100 µL

CD11a (Cris-3), CF740 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
Histone H1 (AE-4), CF647 conjugate, 0.1mg/mL
BNC470096-100 1x 100 µL

Histone H1 (AE-4), CF647 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
P27 / KIP1 (SX53G8), CF568 conjugate, 0.1mg/mL
BNC680669-100 1x 100 µL

P27 / KIP1 (SX53G8), CF568 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
Mucin 5AC (MUC5AC) (58M1), CF647 conjugate, 0.1mg/mL
BNC471003-100 1x 100 µL

Mucin 5AC (MUC5AC) (58M1), CF647 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD34 (ICO-115), CF740 conjugate, 0.1mg/mL
BNC740039-500 1x 500 µL

CD34 (ICO-115), CF740 conjugate, 0.1mg/mL

Sign In for Pricing
View Details